Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 1:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Acetadote Clear all
Terminated Phase 3 Interventional Results available

Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm

NCT00585559
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage, Cerebral Vasospasm
Interventions
Placebos for acetaminophen and N-acetylcysteine, APAP 1 gm every 6 hours and N-acetylcysteine placebo, NAC IV infusion at 0.5 gm hourly and APAP placebo, APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly, APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
20 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Sep 23, 2026, 1:41 AM EDT
Recruiting Phase 2 Interventional

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

NCT04440280
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
N-acetyl cysteine (NAC) 10% solution, N-acetyl cysteine (NAC) 20% solution, Visine Dry Eye Relief eye drops
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 23, 2026, 1:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Glutathione and Function in HIV Patients

NCT02348775
View directory record Official record
Conditions
HIV Infection, Erythrocyte Glutathione Deficiency
Interventions
GlyNAC (combination of glycine and n-acetylcysteine)
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
45 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 23, 2026, 1:41 AM EDT
Recruiting Phase 4 Interventional

Pilon Fracture With Intra-articular Injection of N-Acetylcysteine (Pilon NAC)

NCT03652753
View directory record Official record
Conditions
Pilon Fracture
Interventions
N-acetylcysteine, Saline
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 23, 2026, 1:41 AM EDT
Active, not recruiting Phase 3 Interventional

Oral N-acetylcysteine for Retinitis Pigmentosa

NCT05537220
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
24
States / cities
Davis, California • Los Angeles, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 23, 2026, 1:41 AM EDT
Completed Phase 3 Interventional

Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial

NCT04300920
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
N-acetyl cysteine, Placebo
Drug
Lead sponsor
Fernando J Martinez
Other
Eligibility
40 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
25
States / cities
Tucson, Arizona • Los Angeles, California • Stanford, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 23, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Results available

N-Acetyl Cysteine in Pathologic Skin Picking

NCT01063348
View directory record Official record
Conditions
Pathologic Skin Picking, Neurotic Excoriation, Psychogenic Excoriation, Dermatillomania
Interventions
N-Acetyl Cysteine, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 64 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Sep 23, 2026, 1:41 AM EDT
Completed Phase 4 Interventional Results available

A Clinical Trial Via Telepsychiatry of Treatments for the Management of Emotional Dysregulation in Youth

NCT03911414
View directory record Official record
Conditions
Mood Disturbance, Mood Disorders, Natural Supplements, Alternative Treatment
Interventions
Open-label Treatment with Omega-3 Fatty Acids + Inositol, Open-label Treatment with N-acetylcysteine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 23, 2026, 1:41 AM EDT
Terminated Phase 2 Interventional Results available

Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02569957
View directory record Official record
Conditions
Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Topotecan Hydrochloride, Acetylcysteine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 23, 2026, 1:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

N-acetylcysteine in Alcohol Dependence

NCT00568087
View directory record Official record
Conditions
Alcoholism
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Sep 23, 2026, 1:41 AM EDT
Enrolling by invitation Phase 2Phase 3 Interventional

Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label

NCT05494398
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
N-acetylcysteine
Drug
Lead sponsor
Stanford University
Other
Eligibility
3 Years to 13 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 23, 2026, 1:41 AM EDT
Terminated Phase 3 Interventional Results available

Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD

NCT02411084
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Begelomab, Conventional Second-line Treatment
Biological
Lead sponsor
Adienne SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Duarte, California • Westwood, Kansas • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Sep 23, 2026, 1:41 AM EDT
Completed Phase 2 Interventional

Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke

NCT04918719
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Acetylcysteine, Dextrose in Water
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 23, 2026, 1:41 AM EDT
Completed Phase 1 Interventional

Study of the Safety and Tolerability of ALTH12 Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis

NCT01020708
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
mesalamine, ALTH12-1:4, ALTH12-2:4
Drug
Lead sponsor
Altheus Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Sep 23, 2026, 1:41 AM EDT
Completed Not applicable Interventional Results available

Effect of the Anti-oxidant N-acetylcysteine on Beta-cell Function in Type 2 Diabetes

NCT01394510
View directory record Official record
Conditions
Type 2 Diabetes, Oxidative Stress
Interventions
N-acetylcysteine
Drug
Lead sponsor
Utzschneider, Kristina, M.D.
Individual
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Sep 23, 2026, 1:41 AM EDT
Completed Not applicable Interventional Results available

Effect of Dietary Glycemic Index on Beta-cell Function

NCT01386645
View directory record Official record
Conditions
Impaired Glucose Tolerance, Oxidative Stress, Prediabetes, Impaired Fasting Glucose
Interventions
low glycemic index (LGI) diet, high glycemic index (HGI) diet plus placebo (PLAC), high glycemic index diet plus N-acetylcysteine
Other · Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Sep 23, 2026, 1:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung

NCT00902707
View directory record Official record
Conditions
Mucociliary Clearance
Interventions
Mucinex 1200mg, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Sep 23, 2026, 1:41 AM EDT
Terminated Phase 4 Interventional Results available

Study of N-Acetylcysteine in Acute Liver Failure (ALF)

NCT00896025
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure
Interventions
N-acetylcysteine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 31, 2020 · Synced Sep 23, 2026, 1:41 AM EDT
Terminated Phase 1 Interventional Results available

Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19

NCT04545008
View directory record Official record
Conditions
Covid19
Interventions
Famotidine, N-Acetyl cysteine
Drug
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Easley, South Carolina • Greenville, South Carolina • Greer, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Sep 23, 2026, 1:41 AM EDT
Terminated Not applicable Interventional Results available

N-Acetylcysteine for Patients With COPD and Chronic Bronchitis

NCT01739790
View directory record Official record
Conditions
COPD, Chronic Bronchitis
Interventions
N-Acetylcysteine, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years to 85 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Sep 23, 2026, 1:41 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Dextromethorphan as a Novel Non-opioid Adjunctive Agent for Pain Control in Medication Abortion

NCT03480009
View directory record Official record
Conditions
Abortion in First Trimester
Interventions
Dextromethorphan Hydrobromide, Avicel PH101 (Microcrystalline Cellulose NF) for Compounding, Oxycodone
Drug
Lead sponsor
Study Investigator-Sponsor
Other
Eligibility
18 Years and older · Female only
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 23, 2026, 1:41 AM EDT
Terminated Phase 2 Interventional Results available

MemoryXL Effects on Mild Cognitive Impairment Patients

NCT00903695
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Memory XL, placebo
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
55 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Sep 23, 2026, 1:41 AM EDT
Completed Not applicable Interventional Results available

Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

NCT04073368
View directory record Official record
Conditions
NAFLD
Interventions
AXA1957, AXA1125, Placebo
Dietary Supplement
Lead sponsor
Axcella Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
18
States / cities
Chandler, Arizona • Tucson, Arizona • Huntington Park, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Sep 23, 2026, 1:41 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Treatment of Hemodialysis Catheter-Related Bacteremia

NCT02040818
View directory record Official record
Conditions
Hemodialysis Catheter-related Bacteremia
Interventions
tigecycline, N-acetylcysteine, heparin combination, guide-wire exchange
Drug · Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Sep 23, 2026, 1:41 AM EDT